Neuralink Reports 10,000 People Awaiting N1 Brain-Computer Interface Implant as Clinical Trials Expand

Stock trading depends onGolden Kirin Analyst Research Report, authoritative, professional, timely, and comprehensive, helping you uncover potential thematic opportunities!

(Source: IT Home)

IT Home, October 10 news: According to a report by foreign media outlet PC Mag on the 9th, Dongjin Seo, President and Co-founder of Neuralink, stated that the company has10,000 People Queue for N1 Brain-Computer Interface Chip Implantation. To date, the N1 device has been implanted in 12 clinical trial patients, and Seo expects this number to increase to 25 by the end of the year.

Individuals interested in participating in the clinical trial can register online. Applicants must have limited or complete loss of hand function due to cervical spinal cord injury or ALS (IT Home note: Amyotrophic Lateral Sclerosis, commonly known as “Lou Gehrig’s disease”).

Elon Musk is a co-founder of Neuralink, and Seo is responsible for the company’s day-to-day operations. Seo stated that the 12 patients with implants used the N1 chip for an average of approximately 7.5 hours per day, including one patientMore than 100 hours per week, i.e., approximately 14 hours per day。

The report suggests that this frequent user is likely Noland Arbaugh, Neuralink’s first patient. In a July interview, Arbaugh stated that he uses the device throughout the day to handleEmail, website editing, manuscript writing, research, banking, housework, striving to make a living as an adult.

Seo pointed out, “The latency between user intent and system response is approximately 10 times faster than normal neuromuscular responses; computers are often faster than users expect.” He even joked that Neuralink patients might possess superhuman reaction speeds.Winning an Olympic Esports Medal。

The N1 chip operates on Neuralink’s Telepathy software platform. Morgan Stanley stated that the software reads electrical signals associated with movement or speech via the device’s electrodes, decodes the information, and wirelessly transmits it to the Neuralink application on a computer, where the application performs actions on the screen on behalf of the user.

Seo emphasized that the company’s hardware represents its most significant differentiator from other brain-computer interface companies. The surgical procedure developed by the companyRobotYesImplant the device into the patient's skull, this is an invasive procedure, markedly different from Synchron’s minimally invasive approach.

Morgan Stanley pointed out that Seo stated the company decided from the outset to develop its surgical robot in-house, as the limited number of trained neurosurgeons would become a key bottleneck for scaling if Neuralink were to target the mass market. He also believes that Neuralink’s greatest advantage lies in its deep vertical integration.